Prodrugs, their preparation and use as pharmaceuticals

Details Prodrugs, their preparation and use as pharmaceuticals Prodrugs, their preparation and use as pharmaceuticals

1997-05-20

2000-11-14

Peselev, Elli

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

514 8, 514 23, 514 25, 514 53, 514 54, A23B 403, A61K 3170, A61K 3816

Patent

active

061466581

ABSTRACT:
Glycosyl-spacer-drugs compounds (prodrugs), their preparation and their use as pharmaceuticals are described.

REFERENCES:
patent: 4265885 (1981-05-01), Bargiotti et al.
patent: 4279992 (1981-07-01), Boguslaski et al.
patent: 4481195 (1984-11-01), Rubin
patent: 4975278 (1990-12-01), Senter et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5049549 (1991-09-01), Kolar et al.
patent: 5122368 (1992-06-01), Greenfield et al.
patent: 5132416 (1992-07-01), Tietze et al.
patent: 5137877 (1992-08-01), Kaneko et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5387578 (1995-02-01), Angelucci et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5434247 (1995-07-01), Matteucci et al.
patent: 5561119 (1996-10-01), Jacquesy et al.
R. Duncan et al., "Preclinical evaluation of polymer-bound doxorubicin," J. Controlled Release, vol. 19, Nos. 1/3, (Mar. 1992), pp. 331-346.
Y. Ohya et al., "Synthesis and cytotoxic activity of doxorubicin bound to poly(.alpha.-malic acid) via ester or amide bonds," Macromol. Chem., vol. 193, No. 8, (Aug. 1992), pp. 1881-1887.
V. Subr et al., "Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)-methacrylamide]copolymer drug carriers in vitro and antitumour activity measured in vivo," J. Controlled Release, vol. 18 (1992), pp. 123-132.
"Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy", Papahadiopoulos, et al., Proc. Natl. Acad. Sci. USA, 88:11460-11464 (1991).
"A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice", Okayasu, et al., Gastroenterology 98:694-702 (1990).
"Possible in Situ Activation of Mycophenolic Acid by .beta.-Glucuronidase", Sweeney, et al., Cancer Research 31:477-478 (1971).
"Therapeutic Trial Of Aniline Mustard In Patients With Advanced Cancer", Young, et al., Cancer 38:1887-1895 (1976).
"5-Fluorouracil O-.beta.-D-Glucuronide As A Newly Synthesized Chemically Modified, Nontoxic Anticancer Drug", Baba, et al., Gann 69:283-284 (1978).
"A Novel Connector Linkage Applicable in Prodrug Design", Carl, et al., Journal of Medicinal Chemistry 24(5):479-480 (1981).
"Selective iodination and cytotoxicity of tumor cells with an antibody-enzyme conjugate", Philpott, et al., Surgery 74(1):51-58 (1973).
"Affinity Cytotoxicity of Tumor Cells with Antibody-Glucose Oxidase Conjugates, Peroxidase, and Arsphenamine", Philpott et al., Cancer Research 34:2159-2164 (1974).
"Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation", Bosslet, et al., Br. J. Cancer 65: 234-238 (1992).
"N-(-D-Glycopyranosyl)-Benzyloxycarbonyl Daunorubicine Pro-Prodrugs Synthesis and enzymatic behaviour", Florent, et al., Int. Carbohydr. Symp. Paris, p. 297 (1992).
"N-(-D-Glycopyranosyl)-Nitrobenzyloxycarbonyl Daunorubicine Pro-Prodrugs and enzyme-catalysed hydrolysis", Gesson., et al., Int. Carbohydr. Symp. Paris, p. 298 (1992).
"N-(-D-Glycopyranosyl)-Chlorobenzyloxycarbonyl Daunorubicine Pro-Prodrugs and their enzymatic cleavage", Andrianomenjanahary, et al., Int. Carbohydr. Symp. Paris, p. 299 (1992).
"A modified mouse air pouch model for evaluating the effects of compounds on granuloma induced cartilage degradation", Bottomley, et al., Br. J. Pharmacol. 93:627-635 (1988).
"Immunosuppressive Activity of 15-Deoxyspergualin (15-DOS) on Various Models of Rheumatoid Arthritis", Schorlemmer, et al., Drugs Exptl. Clin. Res. XVII (10/11):471-483 (1991).
"Stimulation of Cell-Mediated Immunity by Bestatin Correlates with Reduction of Bacterial Persistence in Experimental Chronic Salmonella typhimurium Infection", Dickneite, et al., Infection and Immunity 44(1): 168-174 (1984).
Therapeutic Effects of 15-Deoxyspergualin In Acute And Chronic Relapsing Experimental Allergic Encephalomyelitis (EAE) As Models For Multiple Sclerosis (MS), Schorlemmer, et al., Drugs Exptl. Clin. Res. XVII(10/11): 461-469 (1991).
"Curative Effects of 15-Deoxyspergualin On Murine Systemic Lupus Erythematosus-Like Disease In MRL/1 Autoimmune Mice", Schorlemmer, et al., Int. J. Immunotherapy VII(4):169-180 (1991).
"Immunobiochemical and Molecular Biologic Characterization of the Cell Proliferation-associated Nuclear Antigen That Is Defined By Monoclonal Antibody Ki-67", Gerdes, et al., American Journal of Pathology 138(4):867-873 (1991).
"Interleukin 1 (IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis", Cominelli et al., J. Clin. Invest. 86:972-980 (1990).

Affiliated with

Also associated with

Rating

Prodrugs, their preparation and use as pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs, their preparation and use as pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs, their preparation and use as pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2062473